Menopause Hormone Therapy and GLP-1 Drugs: What the New Mayo Clinic Data Can and Cannot Tell You

Two of the most talked-about treatments in women’s health have just been put in the same sentence. The internet has already started treating that sentence like a prescription. New data presented this week at The Menopause Society’s annual meeting suggest that women who use menopause hormone therapy may lose more weight on certain GLP-1 drugs than women who do not. Before you forward the headline to your group chat with three exclamation marks, it helps to read the fine print. The researchers themselves are the first to say the findings are a starting point, not a recipe.

What was presented in San Diego

The Menopause Society is holding its 2026 Annual Meeting from October 20 to 24 at the Hilton Bayfront in San Diego. Among the presentations is a retrospective cohort study titled “Menopause Hormone Therapy and Weight Loss Response to GLP-1-Based Therapies in Midlife Women: A Retrospective Cohort Study.” The lead author is Dr. Regina Castaneda, a postdoctoral research fellow in women’s health at Mayo Clinic Florida.

The team looked back at real-world clinical data from women over 45 with a body mass index above 27 who were treated for overweight or obesity. According to the study summary released for the meeting, about 2,400 women were taking semaglutide, the active ingredient in Ozempic and Wegovy. About 1,500 were taking tirzepatide, sold as Mounjaro and Zepbound. Some coverage describes the sample differently, citing roughly 2,400 participants overall, so the exact breakdown is worth checking once a full paper appears. The researchers compared women who used menopause hormone therapy with women who did not.

The results, without the glitter

For semaglutide, women using hormone therapy showed significantly greater and more sustained weight loss than nonusers. For tirzepatide, the hormone therapy group lost more weight at first, but by the end of treatment the difference was no longer statistically significant. The released materials do not include the actual weight loss percentages, confidence intervals or follow-up times. The work has not yet been published in a peer-reviewed journal.

Castaneda is notably careful about what this means. “While encouraging, these results should be viewed as hypothesis-generating,” she said. She also stressed that hormone therapy has specific medical indications such as bothersome menopausal symptoms. Weight management, she noted, is not one of them. In other words: nobody is suggesting you start hormones to help an injection work better.

Why estrogen might matter

The proposed explanation is biologically plausible, which is scientist speak for interesting but unproven. Castaneda pointed to preclinical research suggesting that estrogen and GLP-1 signaling may work together, possibly amplifying the appetite-suppressing effect of the drugs. Menopause brings a sharp drop in estrogen, so restoring some of it could, in theory, help the medication do its job.

The tirzepatide result fits this idea in an unexpected way. Tirzepatide acts not only on GLP-1 receptors but also on GIP receptors. It also tends to produce larger weight loss on its own. Castaneda described a possible ceiling effect: if a drug already does a lot, there is less room for hormone therapy to add a measurable extra benefit. That is an explanation, not a finding. It would need to be tested directly.

There is a twist worth knowing about. At last year’s Menopause Society meeting, Castaneda presented a retrospective analysis of tirzepatide. After 18 months, postmenopausal women using hormone therapy had lost nearly 20 percent of their body weight, similar to premenopausal and perimenopausal women, while postmenopausal women who had never used hormone therapy lost nearly 15 percent. The new dataset no longer shows a significant end-of-treatment difference for tirzepatide. Science, unlike a makeover show, rarely delivers a clean before-and-after shot.

The limits you should keep in mind

This is an observational study, which means it can show an association but cannot prove that hormone therapy causes extra weight loss. Women who use hormone therapy may differ from those who do not in ways that also affect weight: access to specialist care, overall health, sleep, activity levels or simply how closely they are monitored. Good studies try to adjust for such factors, but a retrospective design can never rule them out completely. The researchers say prospective trials are needed. They also caution that the results apply only to the population and medications studied.

It is also worth separating the science from the culture around it. GLP-1 drugs have become a pop culture phenomenon, discussed on red carpets, in late-night monologues and in the comment sections of every celebrity before-and-after photo. Menopause, meanwhile, spent decades as the topic nobody mentioned at dinner. Kristin Scott Thomas’s famous menopause monologue as Belinda in the second season of Fleabag was celebrated precisely because it said out loud what television usually skipped. Seeing the two topics merge into one hopeful headline is understandable. It is just not yet evidence.

Why the question matters

The reason researchers are asking it at all is that so many women sit at the intersection. Weight gain, especially around the abdomen, is common during the menopausal transition. That kind of weight is linked to higher risks for diabetes and heart disease. According to figures cited in the meeting materials, around 20 percent of women aged 50 to 64 report current or past GLP-1 use. Menopause typically occurs between the ages of 45 and 55. That is a lot of women for whom both treatments may come up in the same doctor’s appointment.

If the association holds up in controlled trials, it could eventually help doctors personalize treatment for midlife women, for example by considering a patient’s hormonal status when choosing a weight loss medication. If it does not hold up, that is useful knowledge too. For now, the most sensible takeaway is the least exciting one: if you have menopausal symptoms, hormone therapy is a conversation to have with your doctor on its own merits. If you are considering a GLP-1 drug, that is a separate conversation. Whether the two belong in one sentence is a question science has only just started to ask.

This article is for general information only and does not replace medical advice. Please talk to your doctor or another qualified health professional about any questions regarding hormone therapy or weight loss medication.